The Nov. 3 legal ruling that the UK government does not have the right to trigger Article 50 to begin the formal two-year process of taking the UK out of the EU without the approval of Parliament means even more uncertainty for the life-sciences sector.
The decision by the High Court of England and Wales could feasibly delay Prime Minister Theresa May’s plan to invoke Article 50 by the end of March 2017
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?